Trending...
- Resident Inspect Joins Property Meld Nexus Network with API Integration
- Philadelphia's First Ginger Store Honored With City Citation for Nine Years of Health and Wellness
- ICTPBX Released: White-Label, Multi-Tenant Open Source PBX Platform for ITSPs
BELLEFONTE, Pa. - PennZone -- Treating alcohol misuse remains a major challenge worldwide. Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options. Some people may respond to a medication that helps with craving, others may respond to a medication that relieves impulsivity, others may respond to a medication that reverses the negative emotional state of withdrawal or protracted withdrawal. Just like any other medical condition, people with alcohol use disorder deserve to have a range of treatment options available to them. Scientists are working to develop a larger menu of pharmaceutical treatments that could be tailored to individual needs.
Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes. The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work. The therapeutic gets delivered accurately to the target and stays there.
Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.
More on The PennZone
"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.
About Actuated Medical, Inc.
Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.
More on The PennZone
More information about Actuated neural device innovations.
See www.actuatedneuroscience.com
NIH Disclaimer.
Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
###
For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.
Additional information can be found by visiting:
https://actuatedmedical.com
https://actuatedneuroscience.com
Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes. The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work. The therapeutic gets delivered accurately to the target and stays there.
Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.
More on The PennZone
- Pollock Begg Partner Joseph R. Williams Featured on 'CEOs You Should Know' Podcast
- Ashley Wineland's 'Love + Heartbreak' Tour Brings her Emotional and Empowering Album 'Wineland' to Nationwide Audiences
- People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
- With a Dream and a Team, Monalisa Okojie Is Empowering the Next Generation Through EXPOSE NGO
- Best Companies Group Launches Best Places to Work in PA Program
"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.
About Actuated Medical, Inc.
Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.
More on The PennZone
- American Properties Realty, Inc. Celebrates 2026 FAME Awards - Community of the Year - Heritage at South Brunswick
- Mel Blackwell to Keynote 2026 NSSF Marketing and Leadership Summit
- SmartCone and Samsung Launch RoadDefender™ to Enhance Real-Time Safety for Roadside Workers
- The Personal Development Industry Has a Blind Spot Says Global Personal Success Guru Omar L. Harris
- Kevin "Mr. Wonderful" O'Leary Begins New Universal Coin & Bullion Promotion of Gold and Silver
More information about Actuated neural device innovations.
See www.actuatedneuroscience.com
NIH Disclaimer.
Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
###
For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.
Additional information can be found by visiting:
https://actuatedmedical.com
https://actuatedneuroscience.com
Source: Actuated Medical, Inc.
0 Comments
Latest on The PennZone
- Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
- VeneerVibe Releases 2026 Snap-On Veneers Market Report
- David Cavanagh Launches AI SEO Company For ChatGPT And AI Search Visibility
- Matthew Cossolotto Spotlights Make a Promise Day 2026 Events, Including Official Launch of Harness Your PromisePower and Issuing a "Peace Promise"
- Landmark Expands Services to Include Specialized Glass and Glazing Solutions Across Los Angeles
- As Pentagon Releases Ufo Files, Debut Ya Novel Predicted It All
- RAATV Premieres Original Reality Series "The Access Index: Jackson" June, 19
- Connecticut Resident Develops Patent-Pending Concept Exploring a New Approach to GPS Navigation
- JP Events Azerbaijan to Host 2nd Women in Motorsport Event During the Azerbaijan Grand Prix Week
- MMA Platform Makes History, Pays Jamey-Lyn Horth After Fans Vote on UFC Winnipeg Robbery
- Resident Inspect Joins Property Meld Nexus Network with API Integration
- Premiere Venue Group Announces $25,000 Sponsorship to Support Ann's Heart Programs and Events
- L2 Aviation Awarded IDIQ Contract by the U.S. Army for M1A2 Abrams Tank
- Sycor.Rental Named Among 2026 Best Microsoft Dynamics ERP Supply Chain Solutions
- KDG Redefines Enterprise Software Development with AI-Assisted and Agentic Delivery Model
- Beyond Medication: Kellyn Foundation And Highmark Wholecare Tackle Type 2 Diabetes, Obesity With Comprehensive Lifestyle Program
- TrueNorth Wellness Services Raises $10,066 During Give Local York 2026
- Smart Tools App Brings 100+ Everyday Utilities Into One Android Solution
- Veikkaus Appoints New CFO as Finland's Gambling Monopoly Braces for Breakup
- Philadelphia's First Ginger Store Honored With City Citation for Nine Years of Health and Wellness
